Eli Lilly will acquire Calytrix Bio, a privately held biotechnology company, in an all-cash transaction whose maximum stated value for the acquisition is $1.5 billion.

Business
Calytrix Bio is a privately held biotechnology company.

Eli Lilly will acquire Calytrix Bio, a privately held biotechnology company, in an all-cash transaction whose maximum stated value for the acquisition is $1.5 billion.
The company expects partnerships to attract another £500 million but has not named potential partners or set a funding timetable.
Reuters reported the proposal implied an equity value of about A$833.7 million (US$564.5 million).
Analysts cited Roche’s diversified business and obesity pipeline, Merck’s growth prospects, and Gilead’s and Sanofi’s quarterly sales gains.